- In the first quarter of 2026, Calumet, Inc. temporarily halted major operations at its Shreveport facility after organic chlorides contaminated feedstock tanks, cutting production by about 750,000 barrels before repairs enabled a return to processing over 50,000 barrels per day.
- The incident highlights both the operational risk embedded in Calumet’s refining footprint and the company’s capacity to restore a key asset relatively quickly.
- We’ll now examine how this unplanned Shreveport outage, and the subsequent return to full operations, may influence Calumet’s investment narrative.
The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Calumet Investment Narrative Recap
To own Calumet, you have to believe the mix of specialty products and renewables can eventually offset high leverage and refining cyclicality, with projects like MaxSAF 150 as key near term proof points. The Shreveport outage underlines how operational hiccups can disrupt volumes, but with production already restored the bigger near term swing factor still sits in renewables execution and regulatory support, while balance sheet risk remains the central overhang.
Against that backdrop, the recent Shreveport disruption puts a spotlight on governance and oversight, which is where the upcoming board refresh matters most. Jennifer Straumins’ planned retirement and the nomination of Bradford T. Sanders, who brings experience in renewables and commodity markets, may shape how Calumet prioritizes reliability, capital allocation, and risk management around projects like MaxSAF and its broader push into higher value products.
Yet behind the recovery at Shreveport, investors should still be aware of how operational risks can interact with Calumet’s already high debt and...
Read the full narrative on Calumet (it's free!)
Calumet's narrative projects $5.1 billion revenue and $40.3 million earnings by 2028.
Uncover how Calumet's forecasts yield a $23.45 fair value, a 32% downside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were expecting revenue to reach about US$5.8 billion and earnings near US$862 million before this outage, yet views differ sharply on whether strong renewables growth really offsets aging assets and high leverage, so it is worth weighing how this new operational setback could shift both the bullish and more cautious narratives.
Explore 3 other fair value estimates on Calumet - why the stock might be worth 32% less than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Calumet research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Calumet research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Calumet's overall financial health at a glance.
Want Some Alternatives?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
- AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com